The Fas (APO-1/CD95) system regulates a number of physiological and pathological processes of cell death. The ligand for Fas induces apoptosis by interacting with a transmembrane cell surface Fas receptor. The key role of the Fas system has been studied mostly in the immune system, but Fas mutations, one of the possible mechanisms for resistance to apoptosis signaling, may be involved in the pathogenesis of non-lymphoid malignancies as well. To better understand the potential involvement of Fas system in non-small cell lung cancer (NSCLC) we evaluated Fas and Fas-ligand mRNA expression by polymerase chain reaction in 102 tumor samples and in 44 normal surrounding tissues. Although over 60% of the human NSCLC analysed expressed both genes, they seem to be unable to induce apoptosis in vivo by autocrine suicide. In this regard, we investigated in 79 cases, the promoter and the entire coding region of the Fas gene by polymerase chain reaction, single strand conformation polymorphism and DNA sequencing for detecting putative alterations. Sixteen tumors (20.25 %) were found to have Fas alterations, in promoter and/or exon region. In all cases samples carried heterozygous alterations and mostly showed simultaneous mutations of p53 gene. Moreover, the quantitative analysis of Fas mRNA expression showed high levels of Fas messenger associated with p53 wild-type status alone. Taken together, these ®ndings point to an involvement of Fas/ Fas-ligand system in the development of NSCLC, suggesting that the loss of its apoptotic function might be linked to p53 alterations which contribute to the selfmaintenance of cancer cells. Oncogene (2001) 20, 6632 ± 6638.
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Keywords: NSCLC; Fas (CD95/APO-1); p53; mutations The Fas receptor protein, also known as APO-1 or CD95, was ®rst identi®ed in 1989 (Yonehara et al., 1989) and subsequently shown to be a member of the tumor necrosis factor (TNF)-receptor superfamily, mapping to the chromosome 10q23 (Lichter et al., 1992) . The majority of human cells express Fas receptor, although at dierent levels (Leithauser et al., 1993; Midis et al., 1996; O'Connell et al., 1997) , and its presence on several neoplastic cells may open new approaches in cancer research.
The Fas ligand is a membrane protein predominantly expressed on natural killer cells and activated T-cells. The link of Fas ligand to Fas receptor induces apoptosis, particularly in cultured human T (Jurkat) cells but also in human B cells, cultured human rhabdomyosarcoma cells (Yonehara et al., 1989) , and murine ®broblast L929 cells and T-cell lymphoma WR19L cells (Itoh and Nagata, 1993; Firestein et al., 1995) . Therefore, the apoptosis induced by the Fas-ligand seems to be predominantly involved in anti-viral immune responses, elimination of tumor cells, and regulation of lymphocyte development. A 150 amino acid sequence at the C-terminus of Fasligand, which is located at the outside of the cell, shares signi®cant homology with members of the TNF family, such as TNF or lymphotoxin (Boussaud et al., 1998; Kashii et al., 1999) . Binding of soluble Fas-ligand (a trimer) or cell-surface-expressed Fas-ligand (whose quaternary structure is unknown) to Fas receptor leads to oligomerization (probably trimerization) of the receptor (Matsumura et al., 2000; Siegel et al., 2000) . This provides for the transmission of the apoptotic signal. Interestingly, it appears that soluble human Fasligand can also antagonize the action of the membranebound form.
Recently, Fas-ligand has also been described on a variety of tumors, including melanoma (Hahne et al., 1996) , colon carcinoma (O'Connell et al., 1996) , astrocytoma (Gratas et al., 1997; Saas et al., 1997) , and lung carcinoma (Niehans et al., 1997) . Moreover, recent evidence suggests a role of Fas/Fas-ligand system in chemotherapy-induced apoptosis. Cytotoxic drugs commonly used in eective chemotherapy of leukemias induce a strong Fas-ligand and Fas expression in tumor cells following drug treatment (MuÈ ller et al., 1997). Up-regulation of Fas by cytotoxic drugs seems to depend on wild-type p53 status (Munker et al., 1995 (Munker et al., , 1996 MuÈ ller et al., 1998) .
Events which initiate or trigger the apoptotic phenomenon may take dierent pathways, depending upon environmental context and apoptotic agents. In order to clarify the involvement of Fas and p53 in apoptotic process, we analysed the Fas/Fas-ligand system and p53-status in a series of non-small cell lung carcinomas and normal surrounding lung tissue, analysing their expression and their genetic assessment, with particular attention given to the simultaneous presence of mutations. 
Quantitation of Fas mRNA expression
On the basis of Fas PCR band-intensity for Fas, we measured its expression using a competitive approach in 77 tumor samples. In order to determine the appropriate amount of Fas competitor to be used in the PCR ampli®cation, we performed a preliminary experiment in which Fas cDNA, obtained by retrotranscription of a constant amount of total RNA, was ampli®ed in the presence of serial dilutions of competitor. The results of these experiments enabled us to perform competitive PCR reactions with this known amount of competitor and cDNA derived from 8 mg of total RNA. A representative electrophoretic analysis of competitive PCR products for Fas appears in Figure 2 .
The mean value of Fas cDNA quantitation (57.93 molecules) allowed us to separate tumors with high (457.93 molecules of Fas cDNA) from tumors with low (457.93 molecules) Fas expression. Seven cases alone showed high Fas mRNA expression and these cases were all Fas ligand positive (w 2 test; P=0.036).
PCR ± SSCP analysis for Fas and p53
The highly-preserved regions of the p53 gene (exons 4 ± 9), the promoter and the coding regions of the Fas gene were ampli®ed by PCR. Altered mobilities of ampli®ed DNA fragments, indicating a structural aberration of the Fas gene, were observed in 16 of the 79 (20.25%) tumor samples; on the contrary, the percentage of p53 mutation was higher (25/40, 62.5%). Figure 3 shows SSCP analysis in samples showing an aberrant electrophoretic pattern of Fas and p53 genes.
Within the Fas gene we identi®ed nineteen aberrant bands: seven in promoter region, seven in exon 3, three in exon 5 and two in exon 7. Three samples concomitantly showed two alterations of the gene. Sequencing analysis of these aberrant bands demonstrated that alterations were mostly missense or involved non-coding regions; only one sense mutation was present in exon 7, resulting in aminoacidic substitution. Interestingly, all the samples showing alterations in the promoter region had the same heterozygosity in position 90. By computer analysis we compared consensus p53-binding site, de®ned by Figure 1 Electrophoretic analysis of PCR products for Fas (upper panel) and of nested-PCR products for Fas ligand (lower panel) on a 1.5% agarose gel containing 0.5 mg/ml ethidium bromide. Lanes L: marker (100-bp ladder, Pharmacia); lanes 1 ± 6: human lung tumor samples. Total RNA was extracted from frozen tissue, primed with random hexamers to synthesize complementary DNA (cDNA) using AMV reverse transcriptase. PCR was carried out in a Perkin-Elmer Thermal Cycler following these conditions: for FAS, cDNAs were ampli®ed for 35 cycles (30 s at 948C, 60 s at 558C, and 60 s at 728C, with a ®nal additional extension step at 728C for 5 min) using primers capable of amplifying a segment from nucleotides 271 to 820 with: FAS 1 5'-CAAGTGACTGACATCAACTCC-3' and FAS 2 5'-CCTTGGTTTTCCTTTCTGTGC-3' (Mitra et al., 1996) ; for FAS-Ligand Nested PCR, cDNAs were ampli®ed for 20 cycles (30 s at 948C, 60 s at 558C, and 90 s at 728C, with a ®nal additional extension step at 728C for 5 min) using these primers: forward 5'-CAGCTCTTCCACCTACAG-3' (position 495) and reverse 5'-TCATGCTTCTCCGTCTTGACATGG-3' (position 1262) (Mitra et al., 1996) . After ampli®cation with this ®rst pair of primers, 8 ml of the product was reampli®ed in 50 ml of fresh reaction mixture, for 30 cycles under the same conditions using a second pair of primers: forward 5'-CTGGGGATGTTT-GAGCTCTTC-3' (position 483) and reverse 5'-CTTCACTCCA-GAAAGCAGGAC-3' (position 693) (Shiraki et al., 1997) Oncogene -Deiry et al. (1992) , with Fas gene-promoter sequence, identifying a putative p53-binding element exactly in the promoter region containing heterozygous alteration in our samples.
On the other hand, sequencing of SSCP-altered band for p53 gene identi®ed mutations resulting in aminoacidic substitution or deletions with frame-shift. Two samples concomitantly showed two alterations of p53, and exon 4 of this gene was always mutated in various spots, often identical in dierent cases.
None of the mutations were present in normal DNA from the same patients, suggesting that aberrant bands did not originate in germline alteration. Detection of Fas and p53 gene mutation were reproducibile through duplicate experiments. There was no correlation between presence of Fas mutations and its mRNA expression, but when alterations of Fas were detected, p53 gene was also mutated (Figure 4 , upper panel; P=0.01). Quantitative PCR showed that high Fas mRNA expression was signi®cantly associated with wild-type p53 ( Figure 4 , lower panel; P=0.0085).
Fas is a cell-surface receptor involved in cell-death signaling. The death signal cascade is initiated in the cross-linking of Fas by its natural ligand. There is now broad evidence demonstrating that malignant cells draw advantage from aberrant loss of Fas and increase Fas-ligand expression, as compared to their normal counterparts. The analysis of Fas and Fas-ligand expression in our series of NSCLC samples points to a higher percentage of Fas-ligand positive cells in tumors than in surrounding normal tissue. On the other hand, although Fas positivity was similar in neoplastic and normal samples, quantitative analysis demonstrated low levels of Fas mRNA in the majority of NSCLC tissues.
Recent observations suggest that tumor cells can exploit the Fas system by down-regulating the expression of functional Fas to resist Fas-ligandmediated killing by cytotoxic T-cells, or by using the Fas system in mounting a`counterattack' for deletion of tumor-in®ltrating T-cells via up-regulation of tumor cell-derived Fas-ligand (O' Connell et al., 1997; Ungefroren et al., 1998; Bennett et al., 1998a) . The result of this`tumor counterattack' could be the depletion of the attacking antitumor lymphocytes by the tumor, immunosuppression and immune escape. This pattern may have relevance in vivo, and the aim of future therapy will be to cause tumor rejection by temporarily-induced T-cell resistance toward apoptosis while maintaining sensitivity in the tumor cells.
To date it is not clear whether NSCLC is resistant to Fas-mediated apoptosis in vivo, but some data have supported this idea; in fact, cell lines from adenocarcinoma showed resistance to Fas-mediated apoptosis, despite expressing Fas (Nambu et al., 1998) . Moreover, in patients with completely resected non-small cell lung stage tumors, those with Fas expression were found to survive longer than those without Fas expression (Uramoto et al., 1999) .
The expression of Fas in tumor samples does not necessarily predict susceptibility to death (Beltinger et al., 1998) ; Fas-mediated apoptosis can be blocked by several mechanisms, including the mutation of the primary structure of Fas (Lee et al., 1999a) or the lack of p53-mediated activation of Fas/Fas-ligand system (Bennett et al., 1998b) . Epigenetic events, including promoter region methylation, were supposed to be contributing factors to the reduction in apoptotic capability of tumors, even if early data do not con®rm this hypothesis (Butler et al., 2000) .
The key role of the Fas system has been studied mostly in the immune system (Nagata, 1997) , and mutations of Fas gene in cancer patients have been described in several lymphoid-lineage malignancies. More recently, somatic mutations of the Fas gene have also been found in solid tumors, such as bladder cancer (Lee et al., 1999b) , malignant melanoma (Rhin et al., 2000) and skin squamous-cell carcinoma (Shin et al., 1999) . Mutations appear to be clonal in the tumor cells, but their functional relevance remains to be established.
Although functional studies have not yet been performed, all the mutations identi®ed in Fas gene in our study are either missense or interest non-coding regions, with no alteration of the normal function of Fas. Only one sense mutation in exon 7 was found, causing aminoacidic substitution. Moreover, our patients carry heterozygous alterations in Fas gene; therefore hemizygously-normal Fas could explain Fas mRNA expression we found in mutated samples.
The low percentage of tumor cells harboring a somatically-mutated Fas gene (26.5% in our work, in accordance with the range 4 ± 28% reported in other studies) suggests that somatic mutation of Fas gene Figure 2 Quantitation of Fas mRNA expression. Lanes 1 ± 4 and 6 ± 9: human lung tumor samples. Lane 5: marker (100-bp ladder, Pharmacia). Lane 10: Fas Competitor alone. In order to obtain the quantitation of Fas mRNA levels we used a technique based on a competitive PCR approach using non-homologous internal standard called Fas competitor. We constructed a 600 bp Fas competitor as previously described : a tritation assay was made to valuate the opportune competitor dilutions to be used. Competitive PCR reactions were then performed adding dilutions of Fas competitor to aliquots of cDNA derived from 8 mg of total RNA. The relative densitometric measure of the electrophoretic bands was then plotted and the point of equal intensity between the bands of competitor PCR MIMIC and target gene was taken as concentration of the cDNA sample Alterations of Fas and p53 genes in non small cell lung cancer (NSCLC) L Boldrini et al does not constitute a unifying event of malignant transformation in lung cancer. Other factors could be involved in the impairment of Fas signaling, justifying the absence of Fas messenger also in samples without alteration of this gene.
Recent evidence suggests an intriguing link between p53 and Fas pathway: infection of p53-resistant cancer cells with adenovirus vector capable of transferring functional human Fas sensitized them to p53-mediated apoptosis (Rakkar et al., 1999) . Moreover, Munsch et al. (2000) reported that intron 1 and promoter of the human Fas death-receptor gene contain a p53- Figure 3 PCR ± SSCP detection of Fas and p53 mutations in human lung tumors (T) in comparison with surrounding normal tissues (P). Tissue samples were mechanically disrupted in liquid nitrogen, lysed by proteinase-K. DNA extraction was then performed using the spin column procedure (QIAamp Tissue Kit, Qiagen). PCR ± SSCP screening for p53 gene and Fas gene mutations: the eluted DNA was used as template in a standard 20 ml-PCR reaction mixture consisting of 10 mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl 2 (pH 8.3), 0.2 mM dNTPs, 8 pmol of each sense and antisense primer, and 1 U of Amplitaq DNA Polymerase (Perkin-Elmer Cetus). PCR analysis for p53 gene was performed using Human p53 Amplimer Panels (CLON-TECH); PCR product sizes for p53 exons 4, 5, 6, 7 and 8 were 307, 211, 185, 139, and 200 bp, respectively . Since all the primers in the Human Amplimer Panels had similar melting temperatures, the same PCR conditions could be used to simultaneously amplify all the exons (in separated reaction tubes). Conditions of p53 exons 4 ± 8, after initial denaturation at 958C (5 min), were 35 cycles of denaturation at 948C for 2 min, annealing at 618C for 2 min, and synthesis at 728C for 3 min, followed by ®nal extension for 10 min. PCR analysis for Fas gene was performed as described by Lee et al. (1999) . PCR product sizes for promoter and exons 1, 2, 3, 4, 5, 7, 8 and 9 were 124, 171, 249, 192, 228, 180, 164, 117 and 191 bp respectively. Conditions of Fas promoter and exons 1 ± 9, after initial denaturation at 948C (5 min), were 40 cycles of denaturation at 948C for 40 s, annealing at 49 ± 608C for 40 s, and synthesis at 728C for 40 s, followed by ®nal extension for 5 min. As negative control, the DNA template was omitted in the reaction. The ampli®cation products were separated on 1.5% agarose gels and visualized by ethydium bromide staining. The PCR products were diluted 1 : 1 with denaturing solution (1% xylene cyanol, 1% bromophenol blue, 0.1 mM EDTA, 99% formamide), boiled for 5 min and thereafter directly placed on ice to prevent reannealing of the single stranded product. SSCP screening for both genes was carried out on the GenePhor Electrophoresis Unit using GeneGel Excel 12.5/24 (12.5% T, 2% C), according to the instructions supplied with the Kit (Pharmacia Biotech). Electrophoresis was performed at 188C, at 600 V, 25 mA, 15 W for 80 min. Gels were stained using PlusOne Silver Staining Kit (Pharmacia Biotech), according to the supplied instructions. Tumour samples demonstrating aberrantly migrating bands in two or more independent PCR ± SSCP runs were considered to contain a mutation. For the detection of mutations, PCR products showing mobility shifts were puri®ed with QIAquick PCR Puri®cation Kit (Qiagen) and sequenced using cyclic sequencing kit (Perkin-Elmer, CA, USA) according to the manufacturer's recommendations responsive element, speci®cally bound only by wildtype p53. Our precedent work analysed p53 status in some NSCLC samples. In the present work, we investigated p53 status in 40 NSCLC, founding p53-mutations in all samples with Fas gene alterations; Fas negative samples showed mutated p53, and high Fas mRNA expression, based on quantitative PCR analysis, was signi®cantly associated with wildtype p53. Accumulation of mutations within p53 gene and within Fas promoter region, containing putative p53-binding site, could progressively silence Fas expression in malignant progression.
In addition to transcriptional regulation of Fas expression by p53, the function of the Fas protein is further regulated by p53, since the transport of Fas protein to the cell surface is also coordinated by p53.
Our results indicate that low or absent expression of Fas in NSCLC is not due to alterations of its gene in the coding region; probably a p53-dependent regulation of Fas system exists with a putative consequent loss of apoptotic function. This loss of function may contribute to the development and maintenance of this type of cancer, suggesting the possibility of therapeutic approaches which aim at reconstructing the function of Fas/Fas-ligand system.
